We are live on ! Find out more
HARP

Harpoon Therapeutics, Inc. Common Stock
HARP

Delisted

HARP was delisted on the 8th of March, 2024.

Back to rankings

42 hedge funds and large institutions have $196M invested in Harpoon Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

950% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 2

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

27% more funds holding

Funds holding: 33 → 42 (+9)

9% more capital invested

Capital invested by funds: $180M → $196M (+$15.4M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
42
Holders Change
+9
Holders Change %
+27.27%
% of All Funds
0.92%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
10
Increased
21
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.17M
2
EC
EcoR1 Capital
California
+$1.62M
3
Northern Trust
Northern Trust
Illinois
+$704K
4
BlackRock
BlackRock
New York
+$393K
5
Renaissance Technologies
Renaissance Technologies
New York
+$385K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$288K
2
Millennium Management
Millennium Management
New York
-$207K
3
Deutsche Bank
Deutsche Bank
Germany
-$35.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
26
American International Group
New York
$63K +$11.4K +81 +21%
Bank of America
27
Bank of America
North Carolina
$58K +$34.6K +246 +132%
Marshall Wace
28
Marshall Wace
United Kingdom
$38K +$38.7K +275 New
JP Morgan Chase
29
JP Morgan Chase
New York
$32K +$10.5K +75 +46%
Deutsche Bank
30
Deutsche Bank
Germany
$27K -$35.4K -252 -55%
TRCT
31
Tower Research Capital (TRC)
New York
$26K +$27K +192 New
Citigroup
32
Citigroup
New York
$25K +$3.23K +23 +15%
Victory Capital Management
33
Victory Capital Management
Texas
$24K +$24.7K +176 New
Legal & General Group
34
Legal & General Group
United Kingdom
$16K +$7.31K +52 +76%
Bank of Montreal
35
Bank of Montreal
Ontario, Canada
$9K +$1.97K +14 +28%
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$8.52K +$1.69K +12 +24%
CCA
37
Catalyst Capital Advisors
New York
$6K – – –
US Bancorp
38
US Bancorp
Minnesota
$4K +$4.22K +30 New
AIP
39
Ameritas Investment Partners
Nebraska
$3K – – –
PCM
40
Prelude Capital Management
New York
$3K +$2.81K +20 New
TFA
41
Toth Financial Advisory
Virginia
$2K +$1.69K +12 New
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$2K +$1.97K +14 +1,400%
Millennium Management
43
Millennium Management
New York
– -$207K -1,593 Closed
1
2

HARP Hedge Fund Activity: Q3 2019 in Review

42 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q3 2019, worth a combined $196M — up 8.6% from $180M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new HARP positions and 1 closed out — a net gain of 9 holders — while 21 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.17M. The largest seller was Deerfield Management, cutting an estimated $288K.

  • 42 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q3 2019, up from 33 in Q2 2019.
  • Funds reported $196M of Harpoon Therapeutics, Inc. Common Stock stock for Q3 2019, up 8.6% quarter-over-quarter.
  • 10 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q3 2019 and 1 closed out, a net change of +9 holders.
  • The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q3 2019 was Vanguard Group, an estimated $2.17M added.
  • The largest Harpoon Therapeutics, Inc. Common Stock seller in Q3 2019 was Deerfield Management, an estimated $288K sold.

Based on aggregated 13F filings for Q3 2019.